Back to feed
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Read the full article at techcrunch#drugs#round#valued#biotech#billion#currently#testing#treat#skin#conditions
to like, bookmark, and comment.
Save Collection
Comments
Join the conversation:
No comments yet. Be the first to share your thoughts.